Progeria is a very rare genetic disease that causes children to age rapidly. Children with progeria appear to be healthy at birth but usually start to show signs of rapid aging in the first 2 years of their life. Most die by about age 13 or 14, although some live into their early 20s. Although progeria is considered an autosomal dominant condition, it is seldom inherited in families.
The two major types of progeria are Hutchinson-Gilford progeria syndrome (HGPS), which has its onset in early childhood, and Werner syndrome (adult progeria) which occurs later in life. Researchers have determined that the cause of HGPS is a single-letter misspelling in a gene on chromosome 1 that codes for lamin A, a protein that is a key component of the membrane surrounding the cell’s nucleus. The abnormal lamin A protein produced in HGPS is called progerin. Treatment for progeria is focused on managing the symptoms. Treatment options may include diet modifications, treatment of heart disease, and physical therapy.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/progeria-market
The Progeria Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Progeria market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Progeria treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Progeria Market Key Facts
According to NORD (n.d.), HGPS is a rare disorder that appears to affect males and females equally, and all races equally. As of January 2014, approximately 200 cases were reported. Estimates indicate that the prevalence of HGPS is about 1 in 18 million, thus at any given time, there are approximately 350–400 children living with progeria worldwide.
Swahari et al. (2015) stated that although the progeroid syndromes are rare (1/4 million live births worldwide for Hutchinson-Gilford Progeria Syndrome (HGPS) and 1/100,000 for WS), the prevalence of WS is particularly high in Japan, where the frequency can range as high as 1/20,000–1/40,000
The study conducted by Swahari et al. (2015), stated that in the United States, the estimated prevalence of HGPS was 1/200,000. Progeria is also 100% fatal, with Werner Syndrome (WS) patients living until the mid-50s and most HGPS patients dying before the age of 20.
As per the study conducted by Sickles et al. (2020), Werner syndrome (WS) is estimated to occur in 1 out of 100,000 live births worldwide. It has a high prevalence in Japan, where the frequency has been reported to be as high as 1 in 20,000–40,000 live births. The prevalence in the United States has been reported as 1 in 200,000 live births.
Key Benefits of Progeria Market Report
Progeria market report provides an in-depth analysis of Progeria Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.
The report will help in developing business strategies by understanding the Progeria Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.
The market report covers the Progeria current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.
The report provides a detailed assessment of the Progeria market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
Progeria market size is expected to increase during the forecast period owing to the rising awareness of the unique histology for the development of drugs that are specific to Progeria. Along with this, the expected launch of emerging therapies will also boost market growth.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Progeria market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Progeria market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Request for Sample @ Progeria Market Therapeutic Market Landscape and Key Companies
The epidemiology section covers insights about the historical and current Progeria patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Progeria Epidemiology Segmentation
Total Prevalent Cases of Progeria
Type-specific Prevalent Cases of Progeria (Hutchinson-Gilford progeria syndrome (HGPS) and Werner syndrome)
Progeria Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Progeria market or expected to get launched in the market during the study period. The analysis covers Progeria market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Progeria Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Progeria market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Progeria emerging therapies.
There is no cure for progeria, but researchers are working on finding one. Specific therapies for individuals with HGPS are symptomatic and supportive. Certain therapies may ease or delay some of the signs and symptoms. Treatments depend on the child’s condition and symptoms.
Key players worldwide are involved in developing therapies for the treatment and prevention of progeria. Several potential therapies for progeria are under investigation which is expected to launch during the forecast period.
PRG Science & Technology
Progeria Therapies covered in the report includes:
Pravastain + lonafarnib + zoledronic acid
And many more.
Request for Sample @ Progeria Novel Therapies and Emerging Technologies
Table of Content
1. Key Insights
2. Executive Summary
3. Progeria Competitive Intelligence Analysis
4. Progeria Market Overview at a Glance
5. Progeria Disease Background and Overview
6. Progeria Patient Journey
7. Progeria Epidemiology and Patient Population
8. Progeria Treatment Algorithm, Current Treatment, and Medical Practices
9. Progeria Unmet Needs
10. Key Endpoints of Progeria Treatment
11. Progeria Marketed Products
12. Progeria Emerging Therapies
13. Progeria Seven Major Market Analysis
14. Attribute Analysis
15. Progeria Market Outlook (7 major markets)
16. Progeria Access and Reimbursement Overview
17. KOL Views on the Progeria Market.
18. Progeria Market Drivers
19. Progeria Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/progeria-market
Latest Reports By DelveInsight
Throat Cancer Market
DelveInsight’s “Throat Cancer Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Throat Cancer market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States